Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study.
about
Cardiac toxicity of trastuzumab in elderly patients with breast cancerUse of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.Specific Aspects of Breast Cancer Therapy of Elderly WomenTwenty years of anti-HER2 therapy-associated cardiotoxicityTreatment of early-stage HER2+ breast cancer-an evolving fieldLong-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer.Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL).Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancerThe Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis.Association of Breast Cancer Knowledge With Receipt of Guideline-Recommended Breast Cancer Treatment.Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients With Breast Cancer.Early-Stage Breast Cancer in the Octogenarian: Tumor Characteristics, Treatment Choices, and Clinical Outcomes.Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort.Treatment of Breast Cancer in the Elderly.Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women With Early-Stage Breast Cancer.Adjuvant chemotherapy in elderly patients with breast cancer: key challenges.Cardiac Complications of HER2-Targeted Therapies in Breast Cancer.Age-related Disparity: Breast Cancer in the Elderly.Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab.Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.Factors associated with radiation therapy incompletion for patients with early-stage breast cancer.Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy.Cardio-oncology: protecting the heart from curative breast cancer treatment
P2860
Q26741182-BB00BF25-8D7E-407E-AF5C-B59A7255C879Q27027354-114D7D8D-DCE5-49BA-9945-0CD175502244Q28079170-3B410AE8-A525-40F2-B81F-97F354005D14Q28079391-B2B7793A-18CF-4B52-A3E5-FE053EFFCB5EQ28081124-8E24FCF6-8A10-4497-80A7-1033EBF6CAB6Q30371966-3E138946-FDC2-4D56-94BA-C7D383D7F4F9Q33824842-03F1430D-6D5E-432F-AD01-142A908AED1CQ33857602-0F32BAC4-34BF-41DB-8230-A58571813402Q34421696-0F0EF93B-E8AD-4F68-80B2-2E9DC9E2E667Q35764604-119DA2DD-822D-4931-87C2-C53DD654D43FQ36761689-97069854-358B-4428-9560-72155094C33DQ37117880-BB85C975-991A-42DF-B937-E96398445879Q37163787-D269758E-47E4-4709-A817-048B84FC8578Q37258848-B63045FB-F0DB-4361-A199-0A7AF1FD7D77Q37612139-16B2D4FC-E12E-4713-A188-3476A9DAABD8Q38594154-C362688C-5B84-4F9F-904C-9DF0F634914FQ38670254-6CE80B3E-55E3-4CF3-9154-BB07D389B684Q38787215-A23C1A2C-FD2B-46FB-A866-0F3A14FAED9DQ38791220-6B4AFCF8-0D0B-4A1D-ADD6-1901EF5E6C4CQ38997213-D2652A36-B292-41E1-9024-C3E209922A0EQ39532324-38DD43CE-9725-467D-AAA8-B77F4C0B9490Q40583931-11016F04-1BC2-4B0E-8006-A9C3A50CCB7DQ41037341-2981F45E-8A31-4115-9CF6-6451C4245FC8Q47575598-1B0BC1EC-E437-4CCE-A1A5-885DAE06CB44Q57108766-44911CD0-4854-47B3-BB7E-180E2D4DCD7C
P2860
Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Duration and toxicity of adjuv ...... cer: a population-based study.
@en
Duration and toxicity of adjuv ...... cer: a population-based study.
@nl
type
label
Duration and toxicity of adjuv ...... cer: a population-based study.
@en
Duration and toxicity of adjuv ...... cer: a population-based study.
@nl
prefLabel
Duration and toxicity of adjuv ...... cer: a population-based study.
@en
Duration and toxicity of adjuv ...... cer: a population-based study.
@nl
P2093
P2860
P356
P1476
Duration and toxicity of adjuv ...... cer: a population-based study.
@en
P2093
Eric P Winer
Huichuan Lii
Ines Vaz-Luis
Nancy L Keating
Nancy U Lin
Rachel A Freedman
P2860
P304
P356
10.1200/JCO.2013.51.1261
P407
P577
2014-02-10T00:00:00Z